338 related articles for article (PubMed ID: 35900317)
41. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Rodriguez-Otero P; Ailawadhi S; Arnulf B; Patel K; Cavo M; Nooka AK; Manier S; Callander N; Costa LJ; Vij R; Bahlis NJ; Moreau P; Solomon SR; Delforge M; Berdeja J; Truppel-Hartmann A; Yang Z; Favre-Kontula L; Wu F; Piasecki J; Cook M; Giralt S
N Engl J Med; 2023 Mar; 388(11):1002-1014. PubMed ID: 36762851
[TBL] [Abstract][Full Text] [Related]
42. Ciltacabtagene autoleucel for the treatment of multiple myeloma.
Holstein SA
Drugs Today (Barc); 2023 Jan; 59(1):1-16. PubMed ID: 36811414
[TBL] [Abstract][Full Text] [Related]
43. BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.
Wu JF; Dhakal B
J Hematol Oncol; 2023 Jul; 16(1):86. PubMed ID: 37507805
[TBL] [Abstract][Full Text] [Related]
44. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.
Parikh RH; Lonial S
CA Cancer J Clin; 2023; 73(3):275-285. PubMed ID: 36627265
[TBL] [Abstract][Full Text] [Related]
45. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z
J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210
[TBL] [Abstract][Full Text] [Related]
46. Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials.
Hu D; Chen L; Yan D; Dong W; Chen M; Niu S; Wang S; Zhang J; Nie X; Fang Y
Front Pharmacol; 2023; 14():1149138. PubMed ID: 37408760
[No Abstract] [Full Text] [Related]
47. Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials.
Xiang X; He Q; Ou Y; Wang W; Wu Y
Front Pharmacol; 2020; 11():544754. PubMed ID: 33343342
[No Abstract] [Full Text] [Related]
48. Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Yamamoto C; Minakata D; Yokoyama D; Furuki S; Noguchi A; Koyama S; Oyama T; Murahashi R; Nakashima H; Ikeda T; Kawaguchi SI; Hyodo K; Toda Y; Ito S; Nagayama T; Umino K; Morita K; Ashizawa M; Ueda M; Hatano K; Sato K; Ohmine K; Fujiwara SI; Kanda Y
Transplant Cell Ther; 2024 Jan; 30(1):118.e1-118.e15. PubMed ID: 37802181
[TBL] [Abstract][Full Text] [Related]
49. Timing of Toxicities and Non-relapse Mortality Following CAR T Therapy in Myeloma.
Wesson W; Dima D; Suleman N; Saif MSI; Tabak C; Logan E; Davis JA; McGann M; Furqan F; Mohan M; Rashid A; Abdallah AO; Ullah F; Shune L; Mushtaq MU; Raza S; McGuirk J; Hamadani M; Anwer F; Hashmi H; Ahmed N
Transplant Cell Ther; 2024 Jun; ():. PubMed ID: 38871056
[TBL] [Abstract][Full Text] [Related]
50. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel J; Dhakal B; Yong K; Spencer A; Anguille S; Mateos MV; Fernández de Larrea C; Martínez-López J; Moreau P; Touzeau C; Leleu X; Avivi I; Cavo M; Ishida T; Kim SJ; Roeloffzen W; van de Donk NWCJ; Dytfeld D; Sidana S; Costa LJ; Oriol A; Popat R; Khan AM; Cohen YC; Ho PJ; Griffin J; Lendvai N; Lonardi C; Slaughter A; Schecter JM; Jackson CC; Connors K; Li K; Zudaire E; Chen D; Gilbert J; Yeh TM; Nagle S; Florendo E; Pacaud L; Patel N; Harrison SJ; Einsele H
N Engl J Med; 2023 Jul; 389(4):335-347. PubMed ID: 37272512
[TBL] [Abstract][Full Text] [Related]
51. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
Zhao WH; Liu J; Wang BY; Chen YX; Cao XM; Yang Y; Zhang YL; Wang FX; Zhang PY; Lei B; Gu LF; Wang JL; Yang N; Zhang R; Zhang H; Shen Y; Bai J; Xu Y; Wang XG; Zhang RL; Wei LL; Li ZF; Li ZZ; Geng Y; He Q; Zhuang QC; Fan XH; He AL; Zhang WG
J Hematol Oncol; 2018 Dec; 11(1):141. PubMed ID: 30572922
[TBL] [Abstract][Full Text] [Related]
52. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma.
Zhang Q; Zu C; Jing R; Feng Y; Zhang Y; Zhang M; Lv Y; Cui J; Zhou L; Meng Y; Wang L; Cen Z; Chang AH; Hu Y; Huang H
Front Immunol; 2023; 14():1125357. PubMed ID: 37215107
[TBL] [Abstract][Full Text] [Related]
53. Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function.
He SL; Cheng YH; Wang D; Xu ML; Que YM; Xu YJ; Ma LM; Li CR; Zhou JF
Curr Med Sci; 2021 Jun; 41(3):474-481. PubMed ID: 34169427
[TBL] [Abstract][Full Text] [Related]
54. SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMM.
Jurgens E; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):277-284. PubMed ID: 38331676
[TBL] [Abstract][Full Text] [Related]
55. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
Costa LJ; Lin Y; Cornell RF; Martin T; Chhabra S; Usmani SZ; Jagannath S; Callander NS; Berdeja JG; Kang Y; Vij R; Godby KN; Malek E; Neppalli A; Liedtke M; Fiala M; Tian H; Valluri S; Marino J; Jackson CC; Banerjee A; Kansagra A; Schecter JM; Kumar S; Hari P
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):326-335. PubMed ID: 34840088
[TBL] [Abstract][Full Text] [Related]
56. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
Feng D; Sun J
Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
[TBL] [Abstract][Full Text] [Related]
57. Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy.
Zhang Q; Zu C; Meng Y; Lyu Y; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):144-150. PubMed ID: 36161293
[TBL] [Abstract][Full Text] [Related]
58. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
Ferment B; Arnulf B
Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
[TBL] [Abstract][Full Text] [Related]
59. Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis.
Soltantabar P; Sharma S; Wang D; Lon HK; Czibere A; Hickmann A; Elmeliegy M
Clin Pharmacol Ther; 2024 Jun; 115(6):1258-1268. PubMed ID: 38459622
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
Cohen AD; Mateos MV; Cohen YC; Rodriguez-Otero P; Paiva B; van de Donk NWCJ; Martin T; Suvannasankha A; De Braganca KC; Corsale C; Schecter JM; Varsos H; Deraedt W; Wang L; Vogel M; Roccia T; Xu X; Mistry P; Zudaire E; Akram M; Nesheiwat T; Pacaud L; Avivi I; San-Miguel J
Blood; 2023 Jan; 141(3):219-230. PubMed ID: 36095849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
